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Abstract 27 
Exposure to hypoxia induces changes in the structure and functional phenotypes of the cells 28 
composing the pulmonary vascular wall from larger to most peripheral vessels.  Endothelial 29 
progenitor cells (EPCs) may be involved in vascular endothelial repair.  Resident EPCs with a high 30 
proliferative potential are found in the pulmonary microcirculation.  However, their potential 31 
location, identification and functional role have not been clearly established.  We investigated 32 
whether resident EPCs or bone marrow (BM)-derived EPCs play a major role in hypoxic response of 33 
pulmonary vascular endothelial cells (PVECs).   34 
Mice were exposed to hypoxia.  The number of PVECs transiently decreased followed by an 35 
increase in hypoxic animals.  Under hypoxic conditions for one week prominent bromodeoxyuridine 36 
incorporation was detected in PVECs.  Some Ki67-positive cells were detected among PVECs after 37 
one week under hypoxic conditions, especially in the capillaries.  To clarify the origin of 38 
proliferating endothelial cells, we used BM chimeric mice expressing green fluorescent protein (GFP).  39 
The percentage of GFP-positive PVECs was low and constant during hypoxia in BM-transplanted 40 
mice, suggesting little engraftment of BM-derived cells in lungs under hypoxia.  Proliferating 41 
PVECs in hypoxic animals showed increased expression of CD34, suggesting hypoxia-induced gene 42 
expression and cell surface antigen of EPC or stem/progenitor cells markers.  Isolated PVECs from 43 
hypoxic mice showed colony and tube forming capacity.  The present study indicated that hypoxia 44 
could induce proliferation of PVECs, and the origin of these cells might be tissue-resident EPCs. 45 
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Introduction 53 
  Hypoxia causes significant structural remodeling of pulmonary arteries in persons living at high 54 
altitude, (3) and the contribution of hypoxia to those vascular changes is beyond question in a number 55 
of lung diseases. (35)  Sustained exposure to hypoxia induces changes in the structure of pulmonary 56 
arteries, as well as in biochemical and functional phenotypes of each of the cell types composing the 57 
artery from larger, more proximal vessels to the most peripheral vessels in the interalveolar wall.  58 
The cellular and molecular mechanisms may vary at specific locations even within the pulmonary 59 
circulation.  This is because the cellular composition of the arterial wall changes along the 60 
longitudinal axis within the pulmonary circulation. (29)  Thus, understanding of the vascular 61 
remodeling induced by hypoxia requires an evaluation of the cells participating at different levels 62 
along the vascular net.   63 
  Although the relationship between hypoxia and proliferation of pulmonary vascular smooth muscle 64 
cells (PVSMCs) has been well established, (20) it is controversial whether proliferation of pulmonary 65 
vascular endothelial cells (PVECs) is directly stimulated by hypoxia. (31, 43)  The structural 66 
changes due to sustained exposure to hypoxia include muscularization of previously non-muscular 67 
arterioles, increased medial thickness of muscular arterioles, adventitial hypertrophy and deposition of 68 
additional matrix components such as collagen and elastin in the wall of pulmonary vessels. (29, 30)  69 
The other major aspect of structural changes caused by hypoxia is rarefaction or pruning, which 70 
means loss of small blood vessels. (21)  Hypoxia-induced loss of blood vessels in the pulmonary 71 
circulation, a widely accepted paradigm, is in contrast to the fact that vascular endothelial growth 72 
factor (VEGF) and its receptors, which induce proliferation of endothelial cells, are expressed in the 73 
lung and hypoxia leads to increased VEGF expression. (34)  In addition, it has been also reported 74 
that chronic hypoxia causes an increase in the number of endothelial cells in intraacinar vessels and 75 
capillaries, indicating new vessel formation. (12)  The mature pulmonary circulation should be 76 
capable of angiogenesis when appropriately stimulated, although the erstwhile concept was that the 77 
adult pulmonary circulation was incapable of supporting the growth of new vessels. 78 
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  Activated endothelial cells may participate in sprouting angiogenesis.  Asahara and colleagues 79 
reported that cells isolated with anti-CD34 or anti-Flk-1 can differentiate into endothelial cells in vitro, 80 
suggesting the presence of circulating endothelial progenitor cells (EPCs) that may be involved in 81 
vascular endothelial repair. (6)  Historically, the EPCs had been shown to derive from bone marrow 82 
(BM).  It is believed that under homeostatic conditions these cells are released from the BM, 83 
circulate in the blood, and contribute to the regenerating process of tissues.  However, there is 84 
increasing evidence to suggest that non BM-derived cells with characteristics of stem/progenitor cells 85 
exist in local tissues.  Schniedermann and colleagues have reported that EPCs with a high 86 
proliferative potential reside in the mouse pulmonary microcirculation and that these EPCs express 87 
CD133, the more immature marker protein. (25)  However, their potential location, identification 88 
and functional role have not been clearly established. 89 
  To date, one technical limitation in this field has been the lack of a specific marker to identify EPCs, 90 
and one important question is the physiological or pathophysiological processes by which these EPCs 91 
could play a role.  In addition, the role of EPCs may change according to the characteristics of 92 
stimuli, including hypoxia. (22)  Taken together, whether resident EPCs or BM-derived EPCs play a 93 
major role in the angiogenic response of PVECs to hypoxia has yet to be determined.  Our previous 94 
data suggested the substantial proliferation of PVECs in response to hypoxia.  We hypothesized that 95 
PVECs might be enriched with EPCs that could be activated under hypoxia.  To clarify the origin of 96 
hypoxia-reactive PVECs, cytological analysis using BM-transplanted mice expressing green 97 
fluorescent protein (GFP) was also performed. 98 
 99 
Methods 100 
Animals and Exposure to Hypoxia 101 
Seven-week-old male C57BL6 mice (Japan CLEA, Tokyo, Japan) were distributed into normoxic 102 
and hypoxic groups.  All mice had free access to food and water.  Mice in the hypoxic groups were 103 
housed in sealed acrylic chambers under 10% O2 (6L/min), which was maintained by an air generator 104 
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(TEIJIN, Tokyo, Japan) for 1, 3, 5, 7 days, 2, or 3 weeks.  O2 concentration was monitored 105 
continuously using an O2 analyzer (JKO-25ML II R; JIKCO, Tokyo).  To avoid the effect of CO2 106 
and NH3 on mice, the environmental conditions were maintained by change of bedding materials and 107 
using CO2 absorber.  All animal procedures were conducted under protocols approved by the Review 108 
Board for animal experiment of Chiba University. 109 
 110 
Bromodeoxyuridine (BrdU) labeling for the detection of proliferating cells  111 
Bromodeoxyuridine (BrdU) is a thymidine analog incorporated into DNA of actively proliferating 112 
cells during the S-phase of the cell cycle.  From the day before flow cytometry (FCM), mice were 113 
given 0.8 mg/ml BrdU (Sigma, St Louis, MO) in their drinking water.  The BrdU solution was 114 
prepared in sterile water, protected from light exposure.  Moreover, 12 and 24 hours before the assay, 115 
mice were intraperitoneally injected with 1 mg of BrdU in phosphate-buffered saline (PBS).   116 
 117 
Lung single cell suspension 118 
For FCM analysis, lung cell dispersion was performed.  After anesthesia was induced by 119 
intraperitoneal injection of pentobarbital, lungs were perfused from the right ventricle with PBS 120 
containing 10 U/ml heparin (Novo- Heparin; Mochida, Tokyo), and collected.  The lungs were 121 
minced using scissors and subjected to enzymatic digestion: Dulbecco`s modified Eagle medium 122 
(DMEM; Sigma) containing 1% of bovine serum albumin (BSA; Wako, Osaka, Japan), 2 mg/ml 123 
collagenase (Wako), 2.5 mg/ml Dispase II (Roche Diagnostics GmbH, Mannheim, Germany), and 100 124 
μg/ml DNase (Wako).  The suspensions were incubated at 37 °C on a shaker for 60 minutes, and 125 
then filtered through a 100 µm nylon mesh screen.  After dispersion of lung cells, the total number of 126 
cells was counted. 127 
 128 
Fluorescence-activated cell sorting analysis 129 
The digested lung cells were pretreated with anti-CD16/32 antibody (BioLegend, San Diego, CA) 130 
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to block Fc receptors, and then stained with a mixture of fluorophore conjugated antibodies in the 131 
dark at 4 °C.  The anti-mouse primary antibodies used were: PE-Cy7-conjugated anti-CD31 132 
(BioLegend), AlexaFluor700-conjugated anti-CD45 (BioLegend), APC-conjugated anti-BrdU (BD 133 
Pharmingen, San Diego, CA), and biotinylated anti-CD34 (BioLegend).  Irrelevant isotype-matched 134 
antibodies were used as controls.  APC-conjugated streptavidin (BioLegend) was used as secondary 135 
antibody.  To measure DNA degradation, the cells were incubated with 10 µg/ml of Hoechst 34580 136 
(Life Technologies, Grand Island, NY) for 30 minutes at 37 °C.  0.5 µg/ml of Propidium iodide (PI; 137 
Sigma) was used to evaluate cell viability.  We took 1×106 cells per sample and 2×105 events were 138 
recorded using a flow cytometer (FACS CantoTM II; BD Biosciences, San Jose, CA).  FCM data was 139 
analyzed using FlowJo software (Tree Star, San Carlos, CA). 140 
 141 
Reactive oxygen species (ROS) generation assay 142 
After surface staining the cells were incubated in PBS containing 40 µM of dichlorofluorescein 143 
diacetate (DCF-DA; Life Technologies, Grand Island, NY) for 30 minutes at 37 °C, to measure 144 
intracellular reactive oxygen species (ROS). 145 
 146 
Aldehyde dehydrogenase (ALDH) activity 147 
To detect cellular aldehyde dehydrogenase (ALDH) activity, ALDEFLUORTM kit (STEMCELL 148 
Technologies, Vancouver, BC, Canada) was used according to the manufacturer’s protocol. 149 
 150 
Magnetic cell separation 151 
For cell culture and DNA extraction from PVECs, PVECs defined as CD31+CD45- cells were 152 
purified from whole lung cells by positive selection using the magnetic cell sorter (AutoMACS; 153 
Miltenyi Biotec, France).  Lungs from normoxic and hypoxia-exposed mice were processed into 154 
single cell suspensions, as described above.  The dissociated lung cells were incubated with 155 
anti-CD16/32 Ab (BioLegend), and then incubated with FITC-conjugated anti-CD31 antibody 156 
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(BioLegend) for 60 minutes at 4 °C followed by incubation with anti-FITC magnetic microbeads 157 
(Miltenyi Biotec) for 15 minutes at 4 °C.  Following filtration (100 µm nylon mesh screen), labeled 158 
cells were sorted, the program “POSSELD”, positive selection through two columns in the magnetic 159 
cell sorter, was run twice and CD31-positive cells were collected.  After cell separation, the 160 
percentage of CD31+CD45- cells in sorted cells was confirmed by FCM.  The purity was greater than 161 
90 %, as previously reported. (41) 162 
 163 
Immunofluorescence staining 164 
The lungs perfused with optimum cutting temperature compound (OCT: SAKURA Finetek, Tokyo) 165 
were embedded in the compound and frozen in liquid nitrogen for tissue sectioning.  166 
Seven-micrometer-thick frozen sections were examined.   167 
The sections were fixed in acetone, blocked using Block Ace (Dainippon Sumitomo Pharma, 168 
Tokyo), and incubated with the primary and secondary antibodies.  The following primary antibodies 169 
were used: Alexa488-conjugated anti-CD31 (BioLegend), Alexa647-conjugated anti-CD45 170 
(Biolegend), anti-Ki67 (Abcam, Cambridge, MA, UK), and Alexa555-conjugated anti-GFP 171 
(Invitrogen, Carlsbad, CA).  Alexa Fluor 488-conjugated anti-rat IgG (BioLegend), Alexa Fluor 172 
555-conjugated anti-rabbit IgG (Life Technologies) and Alexa Fluor 647-conjugated anti-rabbit IgG 173 
(Life Technologies) were used as secondary antibodies, and cell nuclei were counterstained with 174 
Hoechst 34580 (Sigma).  As negative control, isotype controls of each antibody were used. Stained 175 
slides were observed under a confocal fluorescence microscope (Fluoview FV 10i; Olympus, Tokyo) 176 
 177 
Histological quantification 178 
To determine the localization of proliferating PVECs under hypoxic conditions, we separated 179 
pulmonary vessels into two groups by morphology: “arterioles” defined as vessels with visible 180 
vascular lumen and elastic membrane, and “capillaries” defined as flattened vessels.  The percentage 181 
of Ki67-positive cells in PVECs was evaluated in lungs from mice that were under hypoxic conditions 182 
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for seven days. 183 
 184 
Quantitative polymerase chain reaction analysis 185 
Total RNA from whole lung cells and CD31+CD45- cells was purified with the Nucleo Spin RNA 186 
XS and Nucleo Spin RNA II (MACHEREY-NAGEL GmbH & Co. KG, Diiren, Germany) according 187 
to the instructions provided by the manufacturer.  The RNA was transcribed to cDNA using Super 188 
Script VILO™ mastermix (Invitrogen).  Quantitative real-time reverse transcriptase-polymerase 189 
chain reaction (RT-PCR) was performed using the Sequence Detection System ABI prism 7300 190 
(Applied Biosystems, Carlsbad), using the SYBR Green method and the Universal Probe Library 191 
(UPL) method. The SYBR Green method includes Primers (Sigma Genosys) and Fast SYBR Green 192 
Master Mix (Applied Biosystems). The UPL method includes Primers (Sigma Genosys), Universal 193 
Probe Library Extension Set Version 04 (Roche), and FastStart Universal Probe Master (ROX) 194 
(Roche). The levels of gene expression in each sample were determined using the Ct method.  The 195 
Ct values of each sample were normalized with Hprt as the internal control gene and relative gene 196 
expression level was calculated using the 2-∆∆Ct method.  Because an appropriate internal control 197 
gene needs to be used, the following candidates were screened: Actb, Gapdh, Hprt, Rps18, Ywhaz, 198 
and Oaz1.  Among these genes, Hprt was selected as the suitable internal control because its range of 199 
gene expression alteration in normoxic and hypoxic PVECs was the smallest. 200 
 201 
Bone marrow (BM) transplantation 202 
Wild-type C57BL6 mice, 5 weeks of age, were lethally irradiated with 9.5 Gy of radiation divided 203 
into two doses of 5 Gy and 4.5 Gy given 5 hours apart on the day before transplantation.  204 
Unfractionated BM cells (1×107 cells) harvested from the donor mice and ubiquitously expressing 205 
GFP under CAG promoter (Japan SLC, Shizuoka, Japan) were intravenously injected into the 206 
recipient mice.   207 
More than 3 months after BM transplantation, the percentage of GFP-positive cells in peripheral 208 
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blood was confirmed.  After confirmation of BM reconstitution, chimeric mice were kept in hypoxic 209 
chambers for either 1 or 3 weeks 210 
 211 
BM cell infusion to non-irradiated mice 212 
To address the potential influence of irradiation on BM-derived cell incorporation into PVECs, 213 
non-irradiated wild-type mice that were exposed to hypoxia and on days 2 and 6 were intravenously 214 
injected 1×107 BM cells from GFP-expressed mice.  After 1 or 3 weeks under hypoxic conditions, 215 
incorporation of the injected cells into the pulmonary vessels was assessed by FCM.  Normoxic 216 
groups served as controls. 217 
 218 
Evaluation of circulating EPC 219 
The number of circulating EPCs in peripheral blood was evaluated.  Three to five hundred µl of 220 
peripheral blood was collected from the inferior vena cava, and mixed with 100 U of heparin 221 
(Mochida); then red blood cells were lysed by adding 0.2 % saline.  After determining the number of 222 
cells, the samples were incubated first with anti-CD16/32 antibody (BioLegend) and then stained with 223 
the following antibodies: PE-conjugated anti-CD309 (KDR/Flk-1), biotinylated anti-CD34 224 
(eBioscience, San Diego) or biotinylated anti-CD133 (eBioscience) as primary antibodies and 225 
APC-conjugated streptavidin as secondary antibody.  The number of Flk-1+/CD34+ or 226 
Flk-1+/CD133+ cells was evaluated by FCM. 227 
 228 
Colony formation assay 229 
PVECs were isolated from normoxic and hypoxia-exposed (day 7) mice as described above.  230 
These cells were seeded at a cell density of 1×106 cells/well on gelatinized 6-well plates (BD) 231 
supplemented with DMEM (Wako) containing 10 % heated inactivated fetal bovine serum (Wako), 232 
1mM 4-(2-hydroxyethyl)-1-piperazine ethanesulphonic acid (Life Technologies), endothelial cell 233 
growth supplement (Sigma), Primocin (InvivoGen, San Diego), and 12 U/ml heparin (Mochida).  234 
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Nine days after seeding, the colonies that had formed, defined as clusters of 30 or more cells, were 235 
counted. 236 
 237 
Tube formation assay 238 
Isolated PVECs suspended in endothelial cell basal medium-2 (EBM-2; Lonza, Walkersville, MD) 239 
supplemented with EGM-2 MV single aliquots (Lonza) containing 10 % fetal bovine serum were 240 
seeded at a cell density of 4×105 cells/well into 200 µl/well MatrigelTM (BD) coated chamber slides. 241 
These were analyzed for network formation by microscopy. 242 
 243 
Statistical analysis 244 
Quantitative data are presented as mean ± SEM.  Comparison among groups was made using 245 
Student’s t test, Welch’s t test, one-way ANOVA or Kruskal-Wallis test.  GraphPad PRISM software 246 
(Version 6.03; GraphPad Software, San Diego) was used for statistical analysis and figure generation. 247 
 248 
Results 249 
Transient decrease of PVECs was followed by an increase in hypoxic animals 250 
  After murine lung cell dispersion, we counted the number of total lung cells and determined the 251 
percentage of subpopulations by FCM (Figure 1A).  The total number of lung cells decreased on day 252 
5 and then gradually increased to levels beyond the baseline count until two weeks of hypoxia, but 253 
decreased to baseline levels after three weeks of hypoxia. 254 
  As an initial step to quantify subpopulations of lung cells, the percentage of subpopulations with 255 
different CD31 and CD45 expression patterns was analyzed in both unstained control and fluorescent 256 
antibody stained cells (Figure 1B).  Then, the number of PVECs defined as CD31+CD45- cells was 257 
calculated: PVECs = (total lung cell number) × (% of CD31+CD45- cells among total cells)/100.  258 
The change in number of PVECs was similar to that of total lung cells during exposure to hypoxia 259 
(Figure 1C).  After two weeks under hypoxic conditions, the number of PVECs (161.3 ± 16.3 260 
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cells/mice) was significantly higher compared with that on day 5 (85.0 ± 2.63 cells/mice; p = 0.03).  261 
However, the change in percentage of PVECs in whole lung cells was not significant (data not shown).  262 
The result of Hoechst dye staining is presented in Figure 1D and shows that the percentage of 263 
apoptotic PVECs increased on day 5 under hypoxia (normoxic mice; 5.03 ± 0.73 %, vs. hypoxic mice; 264 
8.83 ± 1.11 %).   265 
 266 
Hypoxia during one week induced a prominent incorporation of BrdU into PVECs 267 
   To examine the effect of hypoxia on the proliferative activity of PVECs, hematopoietic cells 268 
(HCs), epithelial cells and PVSMCs, we performed BrdU incorporation experiments.  In FCM 269 
analysis, HCs, epithelial cells and PVSMCs were defined as CD31-CD45+ cells, CD326+/CD31-CD45- 270 
cells and SMA+/CD326-/CD31-CD45- cells, respectively.  The percentage of BrdU-positive cells in 271 
these subpopulations was evaluated.  Representative panels of FCM analyses are shown in Figure 2A.  272 
Under normoxia, BrdU-positive HCs accounted for 6.68 ± 0.60 %, whereas few BrdU-positive cells 273 
were observed among PVECs, epithelial cells and PVSMCs (0.54 ± 0.12 %, 0.59 ± 0.18 %, and 0.38 274 
± 0.07 %, respectively).  However, after a week under hypoxia, the percentage of BrdU-positive 275 
PVECs increased to >10% (Figure 2B).  Moreover, the increase in the percentage of BrdU-positive 276 
PVECs was significantly higher compared with those in HCs, epithelial cells and PVSMCs (Figure 277 
2C and 2D). 278 
 279 
Ki67-positive cells were detected among PVECs after one week under hypoxia, especially in 280 
capillary vessels 281 
  To clarify the localization of proliferating cells in hypoxic lungs, frozen lung samples were 282 
immunohistochemically stained for Ki67, CD31, and CD45 (Figure 3A).  Like BrdU, Ki67 is also a 283 
marker for proliferation.  However, Ki67 protein is present during all active phases of the cell cycle 284 
(G1, S, G2, and mitosis).  After a week under hypoxia, Ki67-positive cells were detected among 285 
PVECs, especially in capillary vessels.  In contrast, the majority of Ki67-positive cells were HCs and 286 
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few Ki67+CD31+ cells were observed under normoxia and after two or three weeks under hypoxia.  287 
These results supported those of the BrdU study by FCM analysis. 288 
  Histological quantification showed that significant proliferation of PVECs occurred in the 289 
capillaries compared with arterioles after a week under hypoxia (Figure 3B). 290 
 291 
The percentage of GFP-positive PVECs was low and constant during 3 weeks under hypoxia in 292 
BM-transplanted mice 293 
  We next investigated whether BM-derived cells directly participate in the pulmonary vasculature 294 
response during hypoxia.  BM obtained from GFP-expressing mice was transplanted to wild-type 295 
irradiated mice.  After dispersion of the lung cells, PVECs and HCs were analyzed by FCM as 296 
described above.  Representative panels of FCM analyses showing BM reconstitution and the 297 
percentage of BM-derived cells in PVECs and HCs are presented (Figure 4A and 4B).  298 
BM-transplanted mice showed a high degree of chimerism (96.1 ± 0.31 %).  Under normoxia, 299 
GFP-positive PVECs accounted for only 1.14 ± 0.17 %, while that of GFP+ HCs was 78.7 ± 1.80 % 300 
(Figure 4C).  The percentages of GFP-positive PVECs and HCs were nearly constant during 3 weeks 301 
under hypoxia.  The number of GFP+/BrdU+PVECs was also low and constant during hypoxia 302 
(Figure 4D and 4E).   303 
 304 
Little engraftment of BM-derived cells was detected in PVECs of chimeric mice under hypoxia 305 
Immunohistochemical analysis was used to evaluate frozen sections from control and hypoxic 306 
GFP-chimeric lungs to determine the extent of mobilization of BM-derived cells.  Under normoxic 307 
conditions, few GFP+CD31+ cells were observed and the majority of GFP-positive cells co-expressed 308 
CD45 in the lungs.  Similarly, few GFP+CD31+ cells were detected in lungs after 1 or 3 weeks under 309 
hypoxia.  In contrast, GFP+CD45+ cells were predominant in peripheral lung tissue (Figure 5A). 310 
  The immunohistological distribution of Ki67-positive cells was examined in the lungs of 311 
GFP-chimeric mice.  Ki67+CD31+ cells were detected in GFP-chimeric mice as well as in 312 
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non-chimeric mice.  However, few GFP+Ki67+CD31+ cells were observed after a week under 313 
hypoxia, and GFP+Ki67+ cells were presumed to be mostly HCs (Figure 5B), suggesting that most of 314 
Ki67+CD31+ cells did not derive from bone marrow. 315 
 316 
There was little tissue integration of injected BM-derived cells in the non-irradiated hypoxic 317 
mice.   318 
To further address the potential influence of irradiation on the incorporation of BM-derived cells 319 
into pulmonary vessels, we intravenously injected BM cells harvested from GFP-expressing mice into 320 
non-irradiated mice that were exposed to hypoxia.  Representative panels of FCM analyses showing 321 
the percentage of GFP-positive cells in PVECs and HCs are presented (Figure 6A and 6B).  Almost 322 
no GFP-positive PVECs were observed at any time point in either normoxic or hypoxic lungs (Figure 323 
6C).  GFP-positive HCs increased after exposure to hypoxia for one week and in controls.  In 324 
addition, the percentage of GFP-positive HCs was not significantly higher in hypoxic lungs compared 325 
with that in normoxic lungs.  However, GFP-positive HCs nearly disappeared after 3 weeks under 326 
hypoxia and in controls (Figure 6D).   327 
 328 
Hypoxia induced mobilization of circulating EPCs 329 
  Under hypoxia, the gene expression of Cxcl12 and Pgf, which are related to the mobilization of 330 
EPCs (38, 40), was significantly increased in whole lung cells (Figure 7A).  To investigate the effect 331 
of hypoxia on the mobilization of EPCs, the number of circulating EPCs, defined as Flk-1+/CD34+ or 332 
Flk-1+/CD133+ cells, was evaluated (Figure 7B).  The number of circulating EPCs increased after a 333 
week under hypoxia (Flk-1+CD34+ cells; 49.9 ± 13.5 × 102 cells/ml, Flk-1+CD133+ cells; 32.3 ± 5.48 × 334 
102 cells/ml) compared with those under normoxia (15.5 ± 2.80 × 102 cells/ml and 23.2 ± 6.78 × 102 335 
cells/ml, respectively), and then after two weeks under hypoxia the number of cells decreased to the 336 
same level observed under normoxia (10.6 ± 1.74 × 102 cells/ml, 14.3 ± 3.15 × 102 cells/ml, 337 
respectively).   338 
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 339 
Proliferating PVECs showed several characteristics of stem/progenitor cells 340 
  Gene expression and cell surface antigen of EPCs markers 341 
  To investigate the characteristics of proliferating PVECs, gene expression of stem/progenitor cell 342 
markers in PVECs was evaluated (Figure 8A).  The percentage of CD31-positive cells in isolated 343 
PVECs were >90 % in normoxic and hypoxia-exposed groups.  Hypoxia increased gene expression 344 
of Prom1 (CD133) and Kit by 2 weeks under hypoxia.  In addition, that of Cd34 significantly 345 
increased from 3 days until 2 weeks.  Actually, CD34-positive PVECs increased gradually until 2 346 
weeks as assessed by FCM (Figure 8B).   347 
  Colony and tube forming capacities 348 
  EPCs possess an intrinsic ability to form colonies and vascular networks in vitro.  To confirm that 349 
the lung contains endothelial cells with a high proliferating capacity as previously reported (25), 350 
PVECs were isolated from normoxic and hypoxic mice by magnetic cell sorting as described above.  351 
The purity of PVECs isolated from normoxic and hypoxic mice was determined as previously 352 
mentioned (95.8 % and 97.4 %, respectively).  The colony formation assay was carried out to 353 
determine the proliferating capacity of PVECs in both groups.  Hypoxic PVECs proliferated rapidly 354 
compared with normoxic PVECs from day 1.  Moreover, the number of colonies with 30 or more 355 
spindle-shaped and cobble stone-like cells per well, in which 1×106 cells were seeded, was compared 356 
between groups.  Representative micrographs of colony formation in hypoxic PVECs are shown in 357 
Figure 8C.  The capacity to form colonies by hypoxic PVECs was significantly higher than that by 358 
normoxic PVECs on day 9.  To test the capability of proliferating PVECs to form capillary tubes, we 359 
performed tube formation assay on MatrigelTM-coated chamber slides (Figure 8D).   We observed 360 
spheroid and adherent cells within 7 days in both groups.  Hypoxic PVECs formed spheres at a 361 
higher frequency than normoxic PVECs.  After 7 days of culture, hypoxic PVECs began to form 362 
tube-like networks, which expanded until day 15, around the spheroid.  In contrast, normoxic PVECs 363 
failed to generate tubes even by day 28 under the same culture conditions. 364 
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  ROS generation 365 
  EPCs have been presumed to be resistant to many stressors including oxidative stress.  We 366 
determined the amount of intracellular ROS in both normoxic and hypoxic PVECs by FCM analysis 367 
using DCF-DA, previously reported as an efficient quantitative marker for cellular oxidant stress 368 
(Figure 9A). (7)  Geometric mean fluorescence intensity of DCF-DA gradually increased until day 5 369 
under hypoxia (1.2-fold), and then decreased to 50 % of that observed under normoxia.  In addition, 370 
the gene expression of Gpx2 increased in hypoxia-exposed PVECs (Figure 9B).   371 
  ALDH activity 372 
  Increased activity of ALDH has been confirmed in hematopoietic and neural stem/progenitor cells.  373 
AldefluorTM fluorescence, which represents ALDH activity, was therefore evaluated in PVECs (Figure 374 
9C).  Under normoxia, 1.05 ± 0.11 % of PVECs expressed ALDH activity.  The percentage of 375 
AldefluorTM-positive PVECs increased by 3 days under hypoxia (1.48 ± 0.27 %), however, it then 376 
gradually decreased.  The expression of Aldh1b1, a gene related to ALDH activity, was enhanced in 377 
regenerating PVECs (Figure 9D).   378 
  Expression of drug resistance genes 379 
One mechanism of cellular protection in EPCs is expression of efflux pumps, which are products of  380 
drug (i.e. toxin) resistance genes.  Figure 9E shows that the relative expression of several 381 
ATP-binding cassette (ABC) transporters such as Abcb1a, Abcb1b, and Abcg1 were slightly enhanced 382 
in hypoxic PVECs. 383 
 384 
Discussion 385 
The results of the present study demonstrate that PVECs responded to exposure to hypoxia for one 386 
week and proliferated especially in the capillaries.  It is well established that hypoxia induces 387 
proliferation of mesenchymal cells such as PVSMCs and fibroblasts, (26, 28) while it remains 388 
controversial whether hypoxia affects proliferation of PVECs and epithelial cells. (39, 43)  Therefore, 389 
the hypoxia-induced proliferation of lung constitutive cell populations such as endothelial and 390 
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epithelial cells has been analyzed in vitro, (10) however, the effects of hypoxia on these cells in vivo 391 
have not been quantitatively evaluated.  In the present study, under steady conditions, the 392 
proliferative ability of PVECs was comparable to that of epithelial and mesenchymal cells, which 393 
exhibit a relatively low proliferative rate. (23)  After 5 or 7 days under hypoxia, most of these cell 394 
populations including HCs showed the highest incorporation of BrdU.  The increase in the rate of 395 
BrdU-positive PVECs was the most remarkable of all cell populations.  The present results support 396 
the proliferation of PVECs, epithelial cells and mesenchymal cells in the face of acute and subacute 397 
hypoxia, with an especially notable increase in PVEC proliferation compared to other cell 398 
components. 399 
The present study showed the proliferating PVECs localized dominantly in the capillaries by 400 
immunohistochemical staining.  In the past, the adult pulmonary circulation was believed to be 401 
incapable of supporting the growth of new vessels.  The structural changes induced by hypoxia have 402 
been thought to include loss of small blood vessels. (29)  Nevertheless, it has also been reported that 403 
hypoxia induces capillary angiogenesis in the adult lung in vivo. (12, 13)  In the lung, microvascular 404 
endothelial cells proliferate approximately twice as fast as macro-arterial endothelial cells. (16)  405 
Moreover, PVECs-derived angiocrine signals might facilitate regenerative alveologenesis as shown in 406 
rats subjected to unilateral pneumonectomy. (9)  The increased capillary bed with accompanied 407 
growth of the alveolar epithelium could be an important contribution for adapting to hypoxia by 408 
increasing the diffusing capacity of the lung thanks to an expansion of the effective surface area of the 409 
alveolar gas exchange membrane. (18)  Thus, the robust proliferation of PVECs observed in this 410 
study might play a beneficial role in the adaptive response to chronic hypoxia.   411 
  Though usually considered to be quiescent, the marked proliferation of the PVECs, whose average 412 
lifespan is more than one year, (1) to adapt a hypoxic environment reminds us of the participation of 413 
EPCs, since EPCs could contribute to angiogenesis and/or vasculogenesis. (6)  Although 414 
BM-derived EPCs are surely important for angiogenesis in many pathophysiological situations (15, 415 
27), the presence of non BM-derived progenitor cells has also been reported.  Recent evidence 416 
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indicates that the vessel wall contains progenitor cells, which have a potential to maintain and repair 417 
the endothelium. (32, 45)  Ingram et al. proposed that vascular wall resident progenitor cells in the 418 
intima of the umbilical vein and aortic vessel wall could contribute to endothelial cell formation. (14)  419 
However, the origin, functions and phenotypes of EPCs are still controversial.  In the present study, 420 
to discriminate whether the proliferating PVECs in hypoxic animals derive from BM or resident 421 
tissues, we generated BM chimeric mice by the transplantation of BM cells expressing GFP into 422 
lethally irradiated wild type mice.  Although hypoxia induced similar proliferation of PVECs in 423 
chimeric mice and in wild type mice, the percentage of GFP-positive PVECs was low and constant 424 
during hypoxia as shown by FCM and immunohistochemical analysis.  Moreover, to avoid the 425 
radiation-induced inflammation and dysfunction of endothelium in recipient mice, BM cells from 426 
GFP-expressing mice were repeatedly injected intravenously into wild type mice during hypoxic 427 
exposure, resulting in almost no BM cell incorporation into the endothelium of normoxic or hypoxic 428 
mice.  These facts indicate that the origin of proliferating PVECs under hypoxia could be local tissue 429 
including tissue resident EPCs.  430 
In this present study, hypoxic PVECs displayed EPC-like characteristics, including 431 
neovasculogenic capacity (in vitro) and anti-oxidative capacity as indicated by a decline in cellular 432 
ROS.  In previous studies, microvascular endothelial cells could be enriched in the tissue-resident 433 
EPCs, which possess proliferative capacity as well as the abilities to form colonies and a vascular 434 
network. (2, 19, 42)  In addition, expression of ABC transporter which related to drug resistance (36), 435 
high ALDH activity (4, 11) and ROS-scavenging capability (8, 37) are considered to be functions of 436 
progenitor cells.  A different study reported that the neovascularization capacity of EPCs from 437 
hypoxic mice was impaired compared to EPCs from control mice. (17)  In our current study, though 438 
several functional features of EPCs were augmented by exposure to hypoxia, others, including ALDH 439 
activity and drug resistance, were not.  EPCs appear to have a tissue-engineering potential under 440 
hypoxic stimulation, though the exact mechanisms of EPCs contribution remain unknown. 441 
 The fact that few BM-derived EPCs were incorporated into the hypoxic pulmonary endothelium 442 
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despite the increased number of circulating EPCs indicates that BM-derived EPCs may not participate 443 
in the hypoxic endothelial response.  Using the hypoxic animal model, several reports showed an 444 
increased number of circulating EPCs.  However, it has been conflicting whether the circulating 445 
EPCs become incorporated into the endothelium, especially based on immunohistochemical 446 
investigations. (17, 24)  The present study showed that hypoxia up-regulated gene expression of EPC 447 
migrating factors such as Cxcl12 and Pgf in whole lung cells, consequently the number of circulating 448 
EPCs increased at the same time proliferation of PVECs occurred.  These data suggest that local 449 
tissue factors are the main participants in PVECs proliferation, while BM-derived endothelial cell 450 
recruitment may be limited.  Circulating EPCs has been considered to consist of at least two distinct 451 
phenotypes, the early and late outgrowth EPCs.  Late outgrowth EPCs that appear after 14-21 days 452 
of culture have a high proliferative rate and the capacity to form vessel structures.  In contrast, 453 
although the early outgrowth EPCs identified after 4-7 days of culture have a low proliferative 454 
capacity, they secrete potent angiogenic factors that accelerate the proliferation and migration of late 455 
outgrowth EPCs, pre-existing endothelial cells and tissue-resident progenitor cells. (5, 15, 33, 44)  In 456 
our study, circulating EPCs could be considered to have characteristics of early outgrowth EPCs.  In 457 
the development of revascularization therapy with EPCs, these findings suggest the importance of 458 
elucidating the mechanism of EPCs-endothelial cells interactions. 459 
      A couple of limitations should be mentioned in the present study.  We showed the existence 460 
of tissue-resident EPCs which proliferated under hypoxia in the lung.  However, these cells were 461 
only a small fraction of PVECs. The functional features of EPCs that we indicated might be affected 462 
by existence of non-EPCs, since characteristics of proliferating PVECs were analyzed using whole 463 
PVECs.  Expression of stem cell markers, such as CD133 and c-kit, did not show a significant 464 
increase.  In the tube formation assay, hypoxic PVECs formed tube structures later than the 465 
timeframe previously reported for EPCs and the structures themselves were defective.  In addition, 466 
our method using standardized protocol with chimeric mice cannot exclude the possibility that tissue 467 
resident progenitor cells may have been mobilized from organs such as the liver and intestine.  468 
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Further, the molecular mechanism by which EPCs would regulate PVECs proliferation has not been 469 
defined.   470 
  In conclusion, the present study demonstrates that hypoxia induced notable proliferation of 471 
PVECs, especially in capillary vessels.  We conclude that tissue-resident EPCs might play a direct 472 
role in hypoxic response of PVECs, while BM-derived EPCs participate indirectly.  As for the lung 473 
tissue destruction/repair in acute respiratory failure and chronic hypoxia-induced lung involvement 474 
including pulmonary vascular remodeling, it is necessary to elucidate the pathobiological conditions 475 
and find therapeutic targets to analyze the cells with high activity that constitute lung tissue.  476 
Therefore, this investigation of the origin and characteristics of proliferating PVECs in acute and 477 
prolonged hypoxia is important for further research. 478 
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 626 
Figure legends 627 
 628 
Figure 1.  Pulmonary vascular endothelial cells (PVECs) kinetics over the course of hypoxic 629 
exposure in mice.  (A) Number of total lung cells decreased on day 5 of hypoxia, and then 630 
significantly increased on day 14.  (B) The representative flow cytometry (FCM) panels of unstained 631 
whole lung cells as control and the cells stained with CD31 and CD45 are shown.  (C)PVECs 632 
decreased on day 5 of hypoxia, and then significantly increased on day 14.  (D) Hypoxia induced 633 
increase in the percentage of apoptotic PVECs on day 5 followed by decrease.  The graphs represent 634 
the integrated values from 4-10 independent experiments.  Values are means ± SEM, *p < 0.05. 635 
 636 
Figure 2.  Bromodeoxyuridine (BrdU) incorporation in PVECs.  (A) The representative FCM 637 
panels of BrdU+ cells in PVECs are shown.  (B) The percentage of BrdU+ PVECs significantly 638 
increased on day 7, and then decreased to the baseline levels.  (C, D) Comparison of BrdU 639 
incorporation in each cell type showed that hypoxia-induced BrdU incorporation into PVECs was 640 
prominent compared with that in the other cells.  The graphs represent the integrated values from 641 
4-10 independent experiments.  Values are means ± SEM, *p < 0.05. 642 
 643 
Figure 3.  Localization of proliferating PVECs in hypoxic mice.  (A) Representative 644 
immunofluorescence images obtained by confocal microscopy are shown.  Blue, red, and yellow 645 
indicate CD31, Ki67, and CD45, respectively.  There were few proliferating PVECs defined as 646 
Ki67+CD31+CD45- cells in both arterioles and capillaries under normoxic conditions.  On day 7, 647 
Ki67+ PVECs were observed especially in capillaries.  However, on days 14 and 21, the number of 648 
Ki67+ PVECs declined to the same levels as those observed under normoxia.  (B) Histological 649 
quantification revealed that the percentage of Ki67+ PVECs increased significantly in capillaries 650 
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compared with arterioles after a week under hypoxia.  Values are means ± SEM, *p < 0.05.  Bars: 651 
20 µm. 652 
 653 
Figure 4.  GFP+ BM cells in the hypoxic lung of BM-transplanted mice.  (A, B) Representative 654 
FCM panels of GFP+ cells in peripheral blood, PVECs and hematopoietic cells (HCs) are shown.  655 
(C) Under normoxia, the percentages of GFP+ cells in peripheral blood cells and HCs were 96.1 ± 656 
0.31 % and 78.7±1.80 %, respectively.  However, that of GFP+ PVECs was only 1.14±0.17 %.  (D) 657 
The percentages of GFP+ PVECs and the number of GFP+/BrdU+PVECs were low and nearly constant 658 
during 21 days under hypoxia.  (D) The percentage of GFP+ cells in HCs was also nearly constant 659 
during hypoxia.  Values are means ± SEM, *p < 0.05. 660 
 661 
Figure 5.  Immunohistochemical analysis in lung sections from BM chimeric mice exposed to 662 
hypoxia.  Representative images obtained by confocal microscopy are shown.  Blue, green, yellow, 663 
and red indicate CD31, GFP, CD45, and Ki67, respectively.  (A) In normoxic animals, the majority 664 
of GFP+ cells co-expressed CD45.  In hypoxic animals, small number of GFP+CD31+ cells was 665 
detected in both arterioles and capillaries.  (B) Immunofluorescence images of chimeric mice 666 
showed that Ki67+CD31+ cells increased on day 7.  However, most of these cells did not co-express 667 
GFP.   668 
 669 
Figure 6.  Incorporation of injected BM cells into hypoxic lung of non-irradiated mice.    (A, 670 
B) Representative FCM panels of GFP+ cells among PVECs and HCs.  (C) Few GFP+ PVECs that 671 
had been infected with BM from mice that expressed GFP were detected at any time point in both 672 
normoxic and hypoxic animals.  (D) GFP+ HCs temporarily increased by one week under hypoxia 673 
and in the control group, however, they failed to engraft. 674 
 675 
Figure 7.  Hypoxia-induced recruitment of EPCs into circulation..    (A) The mRNA levels of 676 
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Pgf and Cxcl12 were enhanced under hypoxia.  (B) The number of Flk-1+CD34+ and Flk-1+CD133+ 677 
cells in peripheral blood increased on day 7, followed by a decrease to the same level observed under 678 
normoxia.  Values are means ± SEM, *p < 0.05. 679 
 680 
Figure 8.  Assesment of vasculogenic capacity, which EPCs was presumed to possess, in 681 
proliferating PVECs.  (A) Time-course qPCR analysis of isolated PVECs showed that Cd34 was 682 
significantly upregulated during hypoxia.  (B) CD34+ PVECs increased until day 14 under hypoxia.  683 
(C) On day 9 of culture, the number of colonies, derived from hypoxic PVECs was significantly 684 
higher than that of colonies derived from normoxic PVECs.  Representative cell colonies observed 685 
on day 9 of culture are shown.  (D) Hypoxic PVECs exhibited tube-like structures from day 7 of 686 
culture.  However, normoxic PVECs exhibited only sphere-like colony formations.  Representative 687 
sphere-like colonies and tube-like formations are shown.  Values are means ± SEM, *p < 0.05, **p < 688 
0.01.  Bars: 100 µm. 689 
 690 
Figure 9.  Anti-oxidative stress capacity and ALDH activity as a stem cell marker in hypoxic 691 
PVECs.  (A) Higher fluorescence intensity of oxidized DCF-DA was observed on day 5 under 692 
hypoxia, and then it gradually decreased until day 14 to 50% of the normal level.  Expression of 693 
Gpx2 was enhanced under hypoxia.  (B) The proportion of Aldefluor+ PVECs slightly increased on 694 
day 5 under hypoxia, and then it decreased until day 21.  The expression of Aldh1b1 was enhanced 695 
under hypoxia.  (C) The expression of drug resistance genes such as ATP-binding cassette 696 
transporters was not significantly enhanced under hypoxia.  Values are means ± SEM. 697 
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